Mode
Text Size
Log in / Sign up

Oncology

1582 published articles · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Iterative skin-directed radiotherapy provides safe palliation for extensive cutaneous metastases in metastatic colorectal cancer
Oncology Sys. Review
Iterative skin-directed radiotherapy provides safe palliation for extensive cutaneous metastases in metastatic colorectal cancer Radiotherapy Shows Promise for Managing Pain from Skin Cancer
This case report describes the management of a 36-year-old man with metastatic colorectal cancer and cutaneous metastases. The patient achie…
A new case report shows that targeted radiation can manage pain and improve symptoms for patients with skin-related spread from colorectal c…
IVIM MRI parameter D provides reproducible markers for rectal cancer cellularity and treatment response
Oncology Sys. Review
IVIM MRI parameter D provides reproducible markers for rectal cancer cellularity and treatment response IVIM MRI May Help Assess Rectal Cancer Treatment Progress
This narrative review evaluates the clinical utility and reproducibility of IVIM MRI parameters in rectal cancer. The authors conclude that …
A specific type of MRI scan called IVIM may help doctors better understand tumor behavior and how rectal cancer responds to treatment.
Xiaoaiping Injection Plus Chemotherapy Improves Response and Cuts Adverse Effects in Breast Cancer
Oncology Meta-analysis
Xiaoaiping Injection Plus Chemotherapy Improves Response and Cuts Adverse Effects in Breast Cancer Herbal Injection Plus Chemo May Improve Breast Cancer Outcomes
This meta-analysis evaluated Xiaoaiping Injection combined with chemotherapy versus chemotherapy alone in patients with breast cancer. Poole…
A Chinese herbal injection added to chemotherapy was linked to better response rates and fewer gut side effects in breast cancer patients.
Hypofractionated Radiotherapy for High-Risk Breast Cancer Patients Following Modified Radical Mastectomy
Oncology RCT
Hypofractionated Radiotherapy for High-Risk Breast Cancer Patients Following Modified Radical Mastectomy Trial shows hypofractionated radiation is comparable to conventional treatment
A Phase 3 trial demonstrates that hypofractionated radiotherapy provides durable local control and comparable safety to conventional fractio…
A large trial shows that a shorter, more intense radiation schedule for breast cancer patients provides similar long-term results as traditi…
Omission of completion axillary lymph node dissection shows no difference in axillary recurrence rates
Oncology Meta-analysis
Omission of completion axillary lymph node dissection shows no difference in axillary recurrence rates Skipping certain lymph node surgery shows no difference in recurrence
This meta-analysis of 4670 patients with node-positive breast cancer found no significant difference in axillary recurrence between omitting…
New data suggests that skipping a specific lymph node surgery after certain treatments may not increase the risk of cancer returning in the …
Surgery for NCRNNE GI Liver Metastases Tied to Better 1-Year Survival
Oncology Meta-analysis
Surgery for NCRNNE GI Liver Metastases Tied to Better 1-Year Survival Surgery Shows Better Survival for Certain Liver Metastases
This meta-analysis of 10 comparative studies examined surgical treatment of metachronous liver metastases from non-colorectal non-neuroendoc…
Surgery may improve survival for patients with specific types of liver cancer spread from gastrointestinal tumors.
RTK-RAS pathway alterations are more frequent in cholangiocarcinoma than in hepatocellular carcinoma
Oncology Meta-analysis
RTK-RAS pathway alterations are more frequent in cholangiocarcinoma than in hepatocellular carcinoma Genetic markers help distinguish between different types of liver and bile duct cancers
This meta-analysis of genomic and single-cell transcriptomic data identifies a higher burden of RTK-RAS alterations in cholangiocarcinoma co…
New research identifies specific genetic signals that help doctors tell the difference between two similar types of liver cancer.
Individualized treatment planning for synchronous bilateral primary breast cancer is supported by independent lesion characterization
Oncology Sys. Review
Individualized treatment planning for synchronous bilateral primary breast cancer is supported by independent lesion characterization Individualized treatment plans help patients with dual primary breast cancers
This case report and literature review examines 1 case and 7 literature cases of synchronous bilateral primary breast cancer. The authors hi…
Doctors are finding that treating each tumor as a unique case helps patients with cancer in both breasts.
FDA Approves Matulane (procarbazine) for Stage III and IV Hodgkin's Disease
Oncology FDA Approval
FDA Approves Matulane (procarbazine) for Stage III and IV Hodgkin's Disease FDA approves Matulane for advanced Hodgkin's disease in combination therapy
Matulane (procarbazine) has been approved for use in combination with other anticancer drugs for the treatment of Stage III and IV Hodgkin's…
The FDA has approved Matulane (procarbazine) to treat Stage III and IV Hodgkin's disease. It is used with other anticancer drugs in the MOPP…
FDA Approves Riabni (rituximab-arrx) for Non-Hodgkin Lymphoma, CLL, RA, GPA/MPA, and Pemphigus Vulgaris
Oncology FDA Approval
FDA Approves Riabni (rituximab-arrx) for Non-Hodgkin Lymphoma, CLL, RA, GPA/MPA, and Pemphigus Vulgaris FDA Approves Riabni for Five Serious Conditions Including Some Cancers
The FDA approved Riabni, a CD20-directed cytolytic antibody, for adults with non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid …
The FDA approved Riabni, a drug given by IV, to treat five conditions: some lymphomas, a type of leukemia, rheumatoid arthritis, and two rar…
PFS and ORR fall short as OS surrogates in metastatic RCC
Oncology Meta-analysis
PFS and ORR fall short as OS surrogates in metastatic RCC Analysis shows limitations in using certain metrics to predict cancer survival
In metastatic RCC, PFS and ORR show only moderate correlation with OS, with surrogate thresholds that are not statistically significant.
A large analysis of kidney cancer cases suggests that common clinical markers may not reliably predict how long a patient will live.
PD-1/PD-L1 inhibitors with anti-angiogenic drugs achieve 48% ORR in recurrent or metastatic nasopharyngeal carcinoma
Oncology Meta-analysis
PD-1/PD-L1 inhibitors with anti-angiogenic drugs achieve 48% ORR in recurrent or metastatic nasopharyngeal carcinoma New drug combinations show promise for advanced nasopharyngeal cancer
This meta-analysis of 10 independent cohorts from 9 studies evaluates PD-1/PD-L1 inhibitors combined with small-molecule anti-angiogenic dru…
Combining certain immunotherapy drugs with anti-angiogenic agents shows a 48% response rate for patients with advanced nasopharyngeal cancer…